Diseases, Conditions, Syndromes

Orexin receptor 2 agonist improves sleepiness in narcolepsy

For patients with narcolepsy type 1, an orexin receptor 2 agonist, TAK-994, improves measures of sleepiness and cataplexy over eight weeks compared with placebo but is associated with hepatotoxic adverse events, according ...

Medications

FDA approves lumryz for narcolepsy

The U.S. Food & Drug Administration has approved Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Lumryz is an extended-release formulation of sodium oxybate to be taken once ...

Medications

FDA says ADHD med Adderall is in short supply

People with attention-deficit/hyperactivity disorder (ADHD) or narcolepsy may rely on the drug Adderall, but it is in short supply, the U.S. Food and Drug Administration announced Wednesday.

Immunology

A real eye-opener: Narcolepsy bears classic autoimmune hallmarks

Narcoleptics suffer from bouts of sleepiness and sleep attacks, which impair their ability to function in daily life. But the precise cause of narcolepsy has long eluded scientists, and the cure for the devastating neurological ...

page 2 from 5